↓ Skip to main content

Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure

Overview of attention for article published in Journal of the American Heart Association Cardiovascular and Cerebrovascular Disease, January 2017
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
6 X users

Citations

dimensions_citation
2 Dimensions

Readers on

mendeley
40 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure
Published in
Journal of the American Heart Association Cardiovascular and Cerebrovascular Disease, January 2017
DOI 10.1161/jaha.116.004119
Pubmed ID
Authors

Reynaria Pitts, Elise Gunzburger, Christie M. Ballantyne, Philip J. Barter, David Kallend, Lawrence A. Leiter, Eran Leitersdorf, Stephen J. Nicholls, Prediman K. Shah, Jean‐Claude Tardif, Anders G. Olsson, John J. V. McMurray, John Kittelson, Gregory G. Schwartz

Abstract

Aldosterone may have adverse effects in the myocardium and vasculature. Treatment with an aldosterone antagonist reduces cardiovascular risk in patients with acute myocardial infarction complicated by heart failure (HF) and left ventricular systolic dysfunction. However, most patients with acute coronary syndrome do not have advanced HF. Among such patients, it is unknown whether aldosterone predicts cardiovascular risk. To address this question, we examined data from the dal-OUTCOMES trial that compared the cholesteryl ester transfer protein inhibitor dalcetrapib with placebo, beginning 4 to 12 weeks after an index acute coronary syndrome. Patients with New York Heart Association class II (with LVEF <40%), III, or IV HF were excluded. Aldosterone was measured at randomization in 4073 patients. The primary outcome was a composite of coronary heart disease death, nonfatal myocardial infarction, stroke, hospitalization for unstable angina, or resuscitated cardiac arrest. Hospitalization for HF was a secondary endpoint. Over a median follow-up of 37 months, the primary outcome occurred in 366 patients (9.0%), and hospitalization for HF occurred in 72 patients (1.8%). There was no association between aldosterone and either the time to first occurrence of a primary outcome (hazard ratio for doubling of aldosterone 0.92, 95% confidence interval 0.78-1.09, P=0.34) or hospitalization for HF (hazard ratio 1.38, 95% CI 0.96-1.99, P=0.08) in Cox regression models adjusted for covariates. In patients with recent acute coronary syndrome but without advanced HF, aldosterone does not predict major cardiovascular events. URL: http://www.clinicaltrials.gov. Unique identifier: NCT00658515.

X Demographics

X Demographics

The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 40 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Netherlands 1 3%
Unknown 39 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 8 20%
Student > Bachelor 5 13%
Student > Doctoral Student 3 8%
Other 3 8%
Student > Master 3 8%
Other 8 20%
Unknown 10 25%
Readers by discipline Count As %
Medicine and Dentistry 15 38%
Pharmacology, Toxicology and Pharmaceutical Science 5 13%
Nursing and Health Professions 3 8%
Biochemistry, Genetics and Molecular Biology 1 3%
Agricultural and Biological Sciences 1 3%
Other 4 10%
Unknown 11 28%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 January 2017.
All research outputs
#14,539,224
of 25,377,790 outputs
Outputs from Journal of the American Heart Association Cardiovascular and Cerebrovascular Disease
#5,249
of 8,237 outputs
Outputs of similar age
#213,744
of 423,375 outputs
Outputs of similar age from Journal of the American Heart Association Cardiovascular and Cerebrovascular Disease
#74
of 131 outputs
Altmetric has tracked 25,377,790 research outputs across all sources so far. This one is in the 42nd percentile – i.e., 42% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,237 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 31.6. This one is in the 35th percentile – i.e., 35% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 423,375 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 49th percentile – i.e., 49% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 131 others from the same source and published within six weeks on either side of this one. This one is in the 41st percentile – i.e., 41% of its contemporaries scored the same or lower than it.